Table 1.

Plasma pharmacokinetic parameters of ixabepilone and total radioactivity in cancer patients after a 3 h intravenous infusion of 70 mg, 80 nCi [¹⁴C]ixabepilone

Nr	Ixabepilone						Radioactivity (ixabepilone equiv.)				AUClast ratioa
	Cmax (ng/ml)	AUClast (μg*h/ml)	AUCinf (μg*h/ml)	t1/2(h)	Cl (l/h)	Vss (l)	Cmax (ng/ml)	AUClast (μg*h/ml)	AUCinf (μg*h/ml)	t1/2 (h)
1	277	3.06	3.35	51.7	20.9	1275	322	1.89	1.96	8.3	1.62b
2	287	2.75	2.97	53.0	23.6	1174	497	11.0	11.8	48.7	0.25
3	433	2.83	2.99	51.7	23.4	929	681	10.9	11.3	36.5	0.26
4	486	3.82	4.32	67.4	16.2	1027	940	20.1	21.6	46.9	0.19
5	266	2.42	2.52	23.5	27.8	756	503	20.0	44.3	185.2	0.12
6	273	2.17	2.29	36.7	30.5	912	573	11.9	16.3	99.8	0.18
7	201	2.25	2.49	71.5	28.1	1520	449	8.53	9.59	61.2	0.26
8	187	1.93	2.22	47.2	31.6	1635	1502	32.5	34.4	34.4	0.06
Mean	301	2.65	2.89	50.3	25.3	1154	683	16.4b	21.3b	73.1b	0.19b
SD	105	0.60	0.69	15.4	5.2	308	378	8.44b	13.2b	54.0b	0.08b

^aAUC_last ratio is calculated by dividing AUC_last ixabepilone by AUC_last TRA and expresses the relative contribution of ixabepilone to TRA exposure in plasma.

^bPatient 1 was not included in the calculation because the radioactivity AUC and t_1/2 could not be determined accurately (see text). This also resulted in the deviating AUC_last ratio (outlier).